Do GLP-1 drugs slow ageing? If you take a GLP-1 drug like semaglutide or tirzepatide, are you getting younger on the inside? At the 2026 Aging Research and Drug Discovery (ARDD) meeting, Novo Nordisk and Eli Lilly stood up and said something close to that: patients on their blockbuster weight-loss drugs came out roughly two to three years younger than placebo on molecular measures of biological age. The claim lit up the longevity world, and it deserves a careful read, because the people making it are also the people selling the drugs.

The short, quotable answer to the question everyone is asking: Novo and Lilly presented company-run analyses showing GLP-1 drugs lowered proteomic and epigenetic estimates of biological age by about two to three years versus placebo in people with obesity or diabetes. The results have not been published in a peer-reviewed journal, the measuring tools have never been validated as health outcomes, and there is zero data on whether the same happens in healthy people. Promising signal, not proof.

What the drugmakers actually presented at ARDD

The Aging Research and Drug Discovery meeting is where longevity scientists go to argue about what actually slows ageing, so it was notable when the two biggest GLP-1 manufacturers showed up with biology data rather than sales figures. According to reporting on the presentations, Novo Nordisk presented blood-draw analyses from 10,052 people, half on semaglutide and half on placebo, with samples taken at the start of the study and months later. Those samples were run through proteomic clocks, which estimate biological age and mortality risk from the levels of key proteins in the blood.

The headline number: roughly two to three years of reversed biological age against placebo, and as much as four years on a clock built specifically from heart-related proteins. Nikolaj Roed, Novo’s global project leader for research and development, told the audience the company had been seeing improved biological age across trials and across different tissues.

Eli Lilly presented a different experiment with the same shape of result. In a sub-study of SURMOUNT-5, researchers applied 15 epigenetic clocks, which estimate age from accumulated DNA modifications, to people on tirzepatide. All 15 clocks showed less biological ageing than the 1.38 years of chronological time that actually elapsed. Kevin Duffin, Lilly’s vice president for aging research, said the clocks consistently showed a reduction in biological age. Steve Horvath, the geneticist who invented the original epigenetic clocks, called the two-year effect strong and described GLP-1 drugs as potential geroprotectors, medications that slow or possibly even reverse biological ageing.

What a biological age clock actually measures

To read this story properly you need to know what the ruler is. An ageing clock is a statistical model trained to predict chronological age, and sometimes mortality risk, from measurable biology. Proteomic clocks read protein levels in blood; epigenetic clocks read methylation patterns on DNA. First-generation clocks were impressive because they predicted age at all. Second-generation clocks go further: they are trained on disease and death outcomes, so a lower score predicts a longer life, at least in the datasets they were trained on.

That “at least” is doing a lot of work. A clock is a surrogate endpoint: it estimates something about you from blood chemistry, and it correlates with outcomes in observational data. But no regulator, and no major medical body, accepts a change in clock score as proof that a drug extends healthy life. When a clock says you are three years younger, it means your blood proteins resemble those of a younger person. It does not mean you have gained three years of life. If you want the full explainer on how these clocks work and where their limits are, our guide to biological age clocks is worth reading before you spend money on any of them.

Do GLP-1 drugs slow ageing? Four reasons the honest read is more modest

Here is where the biohacker mindset helps. Optimisers live by one rule: do not confuse a proxy for the outcome. Four things keep this story in the “interesting, unproven” category.

1. The data comes from the sellers. Both analyses were presented by the manufacturers at a conference, not published in a peer-reviewed journal, and neither company has released the underlying data. An independent critique this month made the obvious point: when the vendor chose the measurement, ran the measurement and reported the measurement, the result is a claim, not a finding. That does not make it wrong, but it means it has not yet survived anyone else’s scrutiny.

2. A clock is not a clinical outcome. The rulers used here have never been validated as drug-trial endpoints. There is no published evidence showing that a three-year improvement on one of these proteomic clocks reliably turns into fewer heart attacks, less dementia or extra years of life. That validation study may happen, but an independent one has not started enrolling. Treating a clock readout as a health result is exactly the kind of surrogate-endpoint error that has burned medicine before.

3. The people were not healthy longevity seekers. Novo’s analysis covered people in trials for obesity and diabetes; Lilly’s epigenetic data came from a weight-loss trial. That matters for two reasons. First, sick populations have more room to improve on blood-based measures, so clock gains may partly reflect the drugs doing their day job: fixing metabolic chaos. Second, nobody knows whether the same signal would appear in healthy older adults who do not need a GLP-1 at all. That is precisely the question a new $38 million US study plans to answer: ARPA-H is funding a Texas trial to test whether semaglutide produces anti-ageing effects, including cognition, mobility and sensory acuity, in healthy people over 60. Results are expected in a year or two.

4. Weight loss alone moves the needle. GLP-1 drugs produce substantial, sustained weight loss, and major weight loss reliably improves many of the same blood markers these clocks read. Critics of the ARDD presentations note the same pattern seen with other dramatic metabolic interventions: when obesity recedes, the blood looks younger. Until the clock effect is shown independently of the kilograms lost, the simplest explanation is that the clocks are reflecting the drugs’ known metabolic benefit rather than a new, distinct anti-ageing mechanism.

Could the clock effect be real biology after all?

Fairness cuts both ways. There are reasons the finding might be more than a statistical artefact. GLP-1 drugs have shown benefits that outrun their weight-loss numbers in heart disease and kidney disease trials, which hints at biology beyond the scales. Lilly also described data pointing to improved survival and physical function at the class level. And the mouse literature on GLP-1 signalling and ageing, while not directly translatable, has been intriguing for years.

But note the standard the biohacking lane has always held: animal data and conference abstracts are hypotheses, not protocols. Nobody should be adjusting their personal longevity strategy on the basis of unreleased company data. The ARDD story sits in the same bucket as the amylin and cellular-energy-sensor headlines from earlier this month: genuine biology worth watching, years away from anything actionable.

The self-experimenter protocol: what to actually do

If you are the kind of person who tracks metrics and iterates, here is the honest protocol this story supports.

Do not take GLP-1 drugs off-label for longevity. Semaglutide and tirzepatide are prescription medicines for diabetes and obesity with real side effects: nausea, vomiting, gallbladder issues, and the well-documented lean-mass loss that accompanies rapid weight loss. The clock data gives zero evidence they help healthy people, and the ARPA-H trial exists precisely because we do not know.

If you are prescribed one, know what the clock tests sell. Consumer biological-age blood tests are not the validated Novo or Lilly clocks, and no company selling them can claim a prescription drug lowers your score. If you track your clock score anyway, treat it as an interesting data point in a spreadsheet, not a verdict on your regimen.

Protect muscle while the science settles. This is the actionable bit hiding inside the story: substantial GLP-1 weight loss includes fat-free mass, and muscle loss is one of the strongest predictors of bad outcomes with age. If you or anyone you know is on a GLP-1, adequate protein and resistance training are the evidence-backed companions, and our guide to what increases lifespan the most covers the interventions with actual outcome data.

Watch the two real milestones. The first is peer-reviewed publication of the Novo and Lilly analyses with independent re-analysis. The second is the ARPA-H healthy-volunteer trial and whatever regulatory path the FDA builds for anti-ageing drugs, because a real indication for healthy ageing would change the entire landscape. Until then, the deepest value on this page is the reminder the ARDD talks could not give themselves: the best-proven longevity levers remain sleep, strength, movement and body composition, the unglamorous inputs we tracked in our habit-stacking and sleep-and-biological-age pieces.

The bottom line for optimisers

GLP-1 drugs really did move molecular ageing clocks by two to three years in company-run analyses of sick populations. That is a genuinely interesting result that deserves the follow-up studies now being planned. It is not evidence that the drugs slow ageing in healthy people, not evidence they extend life, and not a reason to seek a prescription you do not need. The longevity field has been burned before by treating surrogate markers as finish lines. Track the milestones, keep the muscle, and let the peer-reviewed data do the talking.

Frequently asked questions

Sources: New York Post reporting on the ARDD presentations, 11 October 2026; trade coverage of the Novo Nordisk (10,052-person semaglutide analysis, proteomic clocks) and Eli Lilly (SURMOUNT-5 epigenetic sub-study) data; independent critique noting the results are company-presented and unpublished; ARPA-H $38 million semaglutide longevity trial in healthy adults over 60.